recombinant human scd40  (Thermo Fisher)

Journal: iScience

Article Title: PI3K-dependent reprogramming of hexokinase isoforms controls glucose metabolism and functional responses of B lymphocytes

doi: 10.1016/j.isci.2024.110939

Figure Lengend Snippet:

Article Snippet: Human B cell stimulation used 10 ng/mL Goat F(ab’) 2 Anti-human IgM (Southern Biotech #2022-01), 2 ug/mL of recombinant human sCD40 (invitrogen PHP0025), and 10 ng/mL of recombinant human IL-4 (R&D systems, #204-IL/CF).

Techniques: Activation Assay, Marker, Recombinant, Staining, Cell Isolation, Software

Journal: Cell Death & Disease

Article Title: Inhibition of p38 MAPK or immunoproteasome overcomes resistance of chronic lymphocytic leukemia cells to Bcl-2 antagonist venetoclax

doi: 10.1038/s41419-022-05287-6

Figure Lengend Snippet: a Diverse stimulants abrogate venetoclax cytotoxicity against patient-derived CLL cells. Primary cells (1 × 10 6 cells/mL) obtained from nine patients with CLL were treated with 0.1% DMSO (vehicle control), and 1 nM venetoclax alone and in combination with 100 ng/mL IFNγ, 10 nM PMA/1 µM ionomycin, and 100 ng/mL sCD40L for 24 h. The metabolic activities of the cells were determined using the PrestoBlue assay. Data are means ± SEM of ≥ three independent experiments, each carried out in duplicate. Two-way ANOVA (post hoc Tukey); *, **, and **** denote p < 0.05, p < 0.01, and p < 0.0001, respectively; b Cytoprotective effects of IFNγ in the patient-derived CLL cells undergoing spontaneous and venetoclax-induced apoptosis. CLL cells (1 × 10 6 cells/mL) were treated with 0.1% DMSO (vehicle control) and 1 nM venetoclax, 100 ng/mL IFNγ, and their combination for 24 h. Apoptosis was assessed using the SYTOX Blue/annexin V assay. Representative dot plots (left) and means ± SEM of three independent experiments (right) are shown. Two-way ANOVA (post hoc Tukey); *, **, ***, and **** denote p < 0.05, p < 0.01, p < 0.001, and p < 0.0001, respectively; c Nuclear translocation of NFκB in the primary CLL cells. CLL cells (1 × 10 6 c ells/mL) from three patients with CLL were treated with 0.1% DMSO (vehicle control), 100 ng/mL IFNγ, 10 nM PMA/1 µM ionomycin, and 100 ng/mL sCD40L for 1 h. Quantification (left) and representative images (right) are shown for the translocation of NFκB to the nucleus, using imaging flow cytometry. One-way ANOVA (post hoc Dunnett); **** denotes p < 0.0001.

Article Snippet: Recombinant human sCD40 ligand (sCD40L; 310-02) was from PeproTech (London, UK).

Techniques: Derivative Assay, Prestoblue Assay, Annexin V Assay, Translocation Assay, Imaging, Flow Cytometry